| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10007053 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10007054 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10016656 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS10000123 | HBV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS20058066 | HPV | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
| TVIS44025335 | HTLV-1 | ENSG00000128052.10 | protein_coding | KDR | Yes | No | 3791 | P35968 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | KDR |
|---|---|
| DrugBank ID | DB16265 |
| Drug Name | Olinvacimab |
| Target ID | BE0000369 |
| UniProt ID | P35968 |
| Regulation Type | antibody |
| PubMed IDs | 26938715; 28391576; 25188901; 21910042; 26325365 |
| Citations | Tampellini M, Sonetto C, Scagliotti GV: Novel anti-angiogenic therapeutic strategies in colorectal cancer. Expert Opin Investig Drugs. 2016;25(5):507-20. doi: 10.1517/13543784.2016.1161754. Epub 2016 Mar 24.@@Lee SJ, Lee SY, Lee WS, Yoo JS, Sun JM, Lee J, Park SH, Park JO, Ahn MJ, Lim HY, Kang WK, Park YS: Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Invest New Drugs. 2017 Dec;35(6):782-790. doi: 10.1007/s10637-017-0463-y. Epub 2017 Apr 8.@@Kim J, Kim TE, Kim JA, Yun JH, Sohn S, Shim SR, Lee SH, Kim SJ: Intravitreal tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, partially suppresses and regresses laser-induced choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2014 Dec;30(10):847-53. doi: 10.1089/jop.2014.0021.@@Lee SH: Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res. 2011 Aug;34(8):1223-6. doi: 10.1007/s12272-011-0821-9.@@Kim DG, Jin Y, Jin J, Yang H, Joo KM, Lee WS, Shim SR, Kim SW, Yoo J, Lee SH, Yoo JS, Nam DH: Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. MAbs. 2015;7(6):1195-204. doi: 10.1080/19420862.2015.1086854. Epub 2015 Sep 1. |
| Groups | Investigational |
| Direct Classification | |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
